IgA nephropathy
Conditions
Interventions
Sponsors
The First Affiliated Hospital of the Air Force Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 years old; 2. Pathologically diagnosed as primary IgAN, eGFR >= 30mL/min/1.73m2; 3. Initial treatment; 4. The quantity of 24-hour urinary protein is more than 0.75g and less than 3.5g; 5. Agree to participate in this project.
Exclusion criteria
Exclusion criteria: 1. The expected survival time of malignant tumors and other diseases is less than 3 months; 2. Severe cardio-cerebrovascular diseases and pulmonary insufficiency; 3. Complicated with other autoimmune diseases; 4. Diabetes; 5. Gastrointestinal tumors; 6. Gastrointestinal active bleeding; 7. Acute and chronic gastroenteritis; 8. Have previously received or are undergoing FMT treatment; 9. Infect HIV; 10. Mental illness or mental retardation; 11. Pregnant or lactating women within 11 or 18 months; 12. Medical history of alcohol or drug abuse; 13. Serious complications or comorbidities such as elevated aminotransferase more than 2 times the normal value, peripheral white blood cells < 4×10^9/L, deep venous thromboembolism; 14. Atypical IgAN (IgA deposition with glomerular minimal lesion, IgAN with acute renal injury and IgAN with rapidly progressive glomerulonephritis); 15. Other situations that the researchers think are not suitable for participate in this project.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary study outcome would be the 24-hour urinary protein quantity which is less than 0.75g/d during the treatment period (6 months); | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary study outcomes would be clinical remission (partial remission and complete remission), 24-hour urinary protein quantity greater than 3.5g/d, eGFR decrease by 30% from baseline, develop into ESRD and change in urinary occult blood during the treatment period.;The secondary study outcomes would be clinical remission (partial remission and complete remission), recurrence, 24-hour urinary protein quantity greater than 3.5g/d, eGFR decrease by 30% from baseline, develop into ESRD and change in urinary occult blood during follow-up for 6 months; | — |
Countries
China
Contacts
Public ContactShiren Sun
The First Affiliated Hospital of the Air Force Medical University
Outcome results
None listed